The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
Inflammation and immunity in IPF pathogenesis and treatment
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is a progressive, and ultimately fatal, chronic interstitial lung disease characterized by enhanced extracellular matrix deposition. Repetitive alveolar epithelial injury triggers the early development of fibrosis. These injuries, in combination with dysregulated wound repair and fibroblast dysfunction, lead to ongoing tissue remodelling and fibrosis seen in end-stage pulmonary fibrosis. Although the exact etiology in IPF is unknown and probably diverse, all stages of fibrosis are accompanied by innate and adaptive immune responses. The role of inflammation as an important component in IPF etiology is controversial and sometimes seen as an epiphenomenon of fibrosis. This view is partly the result of negative multicenter trials of anti-inflammatory drugs for IPF treatment. However, new insights on the role of macrophages, the loss of T-cell and B-cell tolerance leading auto-immune responses in IPF, and the interaction of immune cells with (myo)fibroblasts have led to a slow change of this opinion. Clearly, more insight is needed to integrate basic immune mechanisms into translational research and finally new IPF therapies. In this concise review, we will focus on the role of our innate and adaptive immune system in the initiation and perpetuation of IPF pathobiology. Next, we will discuss how immune responses are influenced by current anti-fibrotic treatments, such as pirfenidone and nintedanib and end with an overview of recent and upcoming therapeutic trials that target and modulate our immune system in patients with IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–214 of 214
Regulation of pancreatic inflammation by connective tissue growth factor ( CTGF / CCN 2)
Charrier, A., Chen, R., Kemper, S., & Brigstock, D. R. (2013) · Immunology · doi:10.1111/imm.12215 · Cited by 29
Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis
O’Dwyer, D. N., Armstrong, M. E., Kooblall, M., & Donnelly, S. C. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988706 · Cited by 29
Stimulator of Interferon Genes Deficiency in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Qiu, H., Weng, D., Chen, T., Shen, L., Chen, S.-S., Wei, Y., Wu, Q., Zhao, M., Li, Q., Hu, Y., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01756 · Cited by 28
Just, S. A., Lindegaard, H., Hejbøl, E. K., Davidsen, J. R., Bjerring, N., Hansen, S., Schrøder, H. D., Hansen, I. M. J., Barington, T., & Nielsen, C. (2017) · Respiratory Research · doi:10.1186/s12931-017-0623-9 · Cited by 26
Features and roles of T helper 9 cells and interleukin 9 in immunological diseases
Yazdani, R., Shapoori, S., Rezaeepoor, M., Sanaei, R., Ganjalıkhani-Hakemi, M., Azizi, G., Rae, W. M., Aghamohammadi, A., & Rezaei, N. (2018) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2018.02.003 · Cited by 26
Togami, K., Kanehira, Y., & Tada, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00452 · Cited by 24
Lacy, S. H., Epa, A. P., Pollock, S. J., Woeller, C. F., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00565.2016 · Cited by 23
Freynet, O., Marchal-Sommé, J., Jean‐Louis, F., Mailleux, A., Crestani, B., Soler, P., & Michel, L. (2016) · Respiratory Research · doi:10.1186/s12931-016-0345-4 · Cited by 22
Innate lymphoid cells and fibrotic regulation
Horsburgh, S., Todryk, S. M., Ramming, A., Distler, J. H. W., & O’Reilly, S. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.022 · Cited by 18
The effects of pirfenidone on T helper cells in prevention of intraperitoneal adhesions
Özbilgin, K., Üner, M. A., Özkut, M. M., & Hasdemir, P. S. (2017) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2017.03.011 · Cited by 17
TRAIL-Dependent Resolution of Pulmonary Fibrosis
Habiel, D. M., Serezani, A. P. M., Ismailoglu, U. B., Dunleavy, M. P., Cavassani, K. A., van Rooijen, N., Coelho, A. L., & Hogaboam, C. M. (2018) · Mediators of Inflammation · doi:10.1155/2018/7934362 · Cited by 15
IL-13 signaling via IL-13Ralpha2 triggers TGF-beta1-dependent allograft fibrosis
Brunner, S., Schichl, G., Kesselring, R., Martin, M. P., Balam, S., Schlitt, H. J., Geissler, E. K., & Fichtner‐Feigl, S. (2013) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.29517 · Cited by 14
Bianchetti, L., Isgrò, M., Marini, M. A., Bellini, A., Schmidt, M., & Mattoli, S. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.06.002 · Cited by 14
Targeting Th2 cytokines in fibrotic diseases.
Morishima, Y., & Ishii, Y. (2010) · PubMed · Cited by 11
Cited by
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Moss, B. J., Ryter, S. W., & Rosas, I. O. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-030240 · Cited by 821
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation
Moretti, L., Stalfort, J., Barker, T. H., & Abebayehu, D. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101530 · Cited by 393
Peng, L., Wen, L., Shi, Q.-F., Gao, F., Huang, B., Meng, J., Hu, C.-P., & Wang, C.-M. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03178-2 · Cited by 385
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
Metadata
- Authors
- Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M.
- Venue
- Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 147
- Pages
- 79-91
- ISSN
- 0954-6111 (ISSN-L)
- OpenAlex
- W2909223530
- Cited by
- 517
- References
- 214
- FWCI
- 30.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.